Biotechnology company Attogene, based in Austin, Texas, expands its SARS-CoV-2 product line to address the rapidly evolving variant testing demands within the United States.
An efficient and strategic biotech service which helps your team with unique assay and application solutions can ensure that your lab receives the latest testing technology and the skilled service of scientists to help make your journey successful.
Attogene, a biotechnology company based in Austin, Texas, expands its product line to address the rapidly evolving testing demands within the United States, these efforts can have significant public health impact particularly as SARS-CoV-2 continues to mutate around the world.
Specifically, Attogene will now distribute Novacyt’s eight RUO assays, which arguably may be the most complete variant detection portfolio currently available worldwide to address the globally prevalent variants of SARS-CoV-2. The company is also striving to meet all arising COVID-19 challenges as quickly as possible. For example, Novacyt will also have available a new RUO assay to detect a novel variant originally identified in India. Collectively, these efforts reinforce Attogene’s commitment to leadership in responding to the urgent market requirements and public health needs in the U.S. Learn more https://attogene.com/shop/snpsig-variplex-covid-19
Lance P. Ford, PhD, President and CEO of Attogene Corporation said: “We are pleased to be able to provide Novacyt’s state of the art diagnostics to ensure that the country has cutting edge assays to better monitor SARS-CoV-2 variants. We look forward to the opportunity to expand our support of diagnostic testing in the U.S. through our established infrastructure.”
Attogene is a biotechnology company located in Austin, Texas. Attogene’s focus/mission is to provide cutting edge products and services to address major environmental concerns globally. enhance health and wellness of plants, animals and the environment by offering and developing customer focused Life Science Products domestically and internationally. Attogene has additional products and services to address the growing threat from cyanotoxins associated by harmful algae blooms. For more information, visit www.attogene.com
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialization, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly offers microbiology, hematology and serology products with a focus in respiratory and transplantation markets.
For more information, please refer to the website: https://novacyt.com
